<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Regular use of aspirin after a diagnosis of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> has been associated with a superior clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>Experimental evidence suggests that inhibition of <z:chebi fb="11" ids="26333">prostaglandin</z:chebi>-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that the effect of aspirin on survival and prognosis in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha <z:chebi fb="1" ids="15841">polypeptide</z:chebi> gene) might differ from the effect among those with <z:mp ids='MP_0002169'>wild-type</z:mp> PIK3CA <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We obtained data on 964 patients with rectal or <z:hpo ids='HP_0003003'>colon cancer</z:hpo> from the Nurses' Health Study and the Health Professionals Follow-up Study, including data on aspirin use after diagnosis and the presence or absence of PIK3CA mutation </plain></SENT>
<SENT sid="4" pm="."><plain>We used a Cox proportional-hazards model to compute the multivariate hazard ratio for <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>We examined <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers, including PTGS2, phosphorylated AKT, KRAS, BRAF, microsatellite instability, CpG island methylator phenotype, and methylation of long interspersed nucleotide element 1 </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Among patients with mutated-PIK3CA <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, regular use of aspirin after diagnosis was associated with superior <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific survival (multivariate hazard ratio for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo>, 0.18; 95% confidence interval [CI], 0.06 to 0.61; P&lt;0.001 by the log-rank test) and overall survival (multivariate hazard ratio for <z:hpo ids='HP_0011420'>death</z:hpo> from any cause, 0.54; 95% CI, 0.31 to 0.94; P=0.01 by the log-rank test) </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, among patients with <z:mp ids='MP_0002169'>wild-type</z:mp> PIK3CA, regular use of aspirin after diagnosis was not associated with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific survival (multivariate hazard ratio, 0.96; 95% CI, 0.69 to 1.32; P=0.76 by the log-rank test; P=0.009 for interaction between aspirin and PIK3CA variables) or overall survival (multivariate hazard ratio, 0.94; 95% CI, 0.75 to 1.17; P=0.96 by the log-rank test; P=0.07 for interaction) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Regular use of aspirin after diagnosis was associated with longer survival among patients with mutated-PIK3CA <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but not among patients with <z:mp ids='MP_0002169'>wild-type</z:mp> PIK3CA <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The findings from this molecular pathological epidemiology study suggest that the PIK3CA mutation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> may serve as a predictive molecular biomarker for adjuvant aspirin therapy </plain></SENT>
<SENT sid="10" pm="."><plain>(Funded by The National Institutes of Health and others.) </plain></SENT>
</text></document>